Education
About Us
Working with TipRanks
Follow Us
Spero Therapeutics (SPRO)
:SPRO
Earnings Data
Report Date
May 09, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.27Last Year’s EPS
-0.24Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 27, 2025
|% Change Since: -10.47%
|Next Earnings Date:May 09, 2025
Earnings Call Sentiment|Neutral
Spero Therapeutics is advancing its tebipenem HBr program with promising potential and strategic partnerships, but faces challenges with its SPR720 trial results and financial performance, including decreased revenue and increased losses.Company Guidance
During the Spero Therapeutics Fourth Quarter and Full Year 2024 Earnings Conference Call, the company provided key updates on its clinical programs and financial performance. Spero announced that the interim analysis for the Phase 3 PIVOT-PO trial of tebipenem HBr, co-developed with GSK, is expected to be completed in the second quarter of 2025. This trial aims to treat complicated urinary tract infections (cUTI) with a novel oral carbapenem. The company also reported that the SPR720 study did not meet its primary endpoint, with potential dose-limiting safety signals observed, leading to further assessment of the data. Financially, Spero ended the year with $52.9 million in cash and equivalents, generating $48 million in revenue for 2024, a decrease from $103.8 million in 2023, primarily due to reduced collaboration revenue. R&D expenses rose to $97 million due to increased clinical trial activities, while G&A expenses slightly decreased to $23.7 million. The company reported a net loss of $68.4 million for the year, compared to a net income of $22.8 million in 2023.Advancement of Tebipenem HBr Program
Spero Therapeutics announced a prespecified interim analysis in the Phase 3 PIVOT-PO clinical trial for tebipenem HBr, expected to be completed in Q2 2025. This program has the potential to change the treatment paradigm for complicated cUTI by offering an oral treatment option.
Financial Position and Milestones
As of December 31, 2024, Spero had $52.9 million in cash and equivalents. They expect existing funds and development milestones from GSK to support operations into Q2 2026. Potential milestone payments from GSK could total about $400 million, contingent on regulatory and commercialization success.
Pipeline and Strategic Partnerships
Spero is co-developing tebipenem HBr with GSK and expects GSK to assume responsibility for regulatory and commercialization efforts. This partnership could lead to significant milestone payments if successfully pursued.
---
SPRO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SPRO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 27, 2025 | $0.86 | $0.77 | -10.47% |
| Nov 14, 2024 | $1.25 | $1.18 | -5.60% |
| Aug 05, 2024 | $1.34 | $1.27 | -5.22% |
| May 15, 2024 | $1.62 | $1.57 | -3.09% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Spero Therapeutics (SPRO) report earnings?
Spero Therapeutics (SPRO) is schdueled to report earning on May 09, 2025, TBA Not Confirmed.
What is Spero Therapeutics (SPRO) earnings time?
Spero Therapeutics (SPRO) earnings time is at May 09, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SPRO EPS forecast?
SPRO EPS forecast for the fiscal quarter 2025 (Q1) is -0.27.
---